These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 21729991

  • 1. The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease.
    Tsuboi N, Kawamura T, Okonogi H, Ishii T, Hosoya T.
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):113-7. PubMed ID: 21729991
    [Abstract] [Full Text] [Related]

  • 2. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A, Hayashi K, Saruta T.
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [Abstract] [Full Text] [Related]

  • 3. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.
    Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL.
    PLoS One; 2011 Jan; 6(11):e26904. PubMed ID: 22073219
    [Abstract] [Full Text] [Related]

  • 4. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
    Morales E, Millet VG, Rojas-Rivera J, Huerta A, Gutiérrez E, Gutiérrez-Solís E, Egido J, Praga M.
    Nephrol Dial Transplant; 2013 Feb; 28(2):405-12. PubMed ID: 23222416
    [Abstract] [Full Text] [Related]

  • 5. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [Abstract] [Full Text] [Related]

  • 6. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, EVALUATE Study Group.
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [Abstract] [Full Text] [Related]

  • 7. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 8. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 9. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats.
    Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y, Suzuki H.
    Am J Nephrol; 2004 Oct; 24(1):54-60. PubMed ID: 14707436
    [Abstract] [Full Text] [Related]

  • 10. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Oct; 5(5):354-63. PubMed ID: 14503934
    [Abstract] [Full Text] [Related]

  • 11. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 12. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S, Bigazzi R, Campese VM.
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [Abstract] [Full Text] [Related]

  • 13. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009 Dec; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 14. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    Am J Nephrol; 2004 Dec; 24(2):242-9. PubMed ID: 15031627
    [Abstract] [Full Text] [Related]

  • 15. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY, Bae EH, Ma SK, Kim SW.
    Kidney Blood Press Res; 2014 Dec; 39(6):573-80. PubMed ID: 25531940
    [Abstract] [Full Text] [Related]

  • 16. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
    Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B.
    Acta Biochim Pol; 2010 Dec; 57(1):119-23. PubMed ID: 20309434
    [Abstract] [Full Text] [Related]

  • 17. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M, Yamada A, Fujita T, Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators.
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [Abstract] [Full Text] [Related]

  • 18. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B.
    Handb Exp Pharmacol; 2017 Jun; 243():271-305. PubMed ID: 27830348
    [Abstract] [Full Text] [Related]

  • 19. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 20. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S.
    Clin Exp Hypertens; 2005 Sep; 27(2-3):129-38. PubMed ID: 15835375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.